You are here

P&T November 2014

Features

Perspective
A Look Back at the Last Decade and a Look Forward to 2020
Changes related to market forces, regulatory initiatives, and the Affordable Care Act have significantly altered the traditional work of P&T committees. Redefined issues of quality, cost, and access will become even more important in the coming years.
Perspective

Drug therapy aids most epilepsy patients, but unmet challenges include drug-resistant epilepsy, adverse reactions, drug interactions, the need to better identify epileptic syndromes, and a lack of agents to prevent epilepsy and its comorbidities.

Pipeline Plus

The epilepsy market’s $4.2 billion in global sales in 2012 is expected to increase to $5.4 billion by 2022. In a market crowded with products, pharmaceutical companies have shifted their focus to devising safe adjunctive therapies for refractory patients.

Meeting Highlights

In these two major cardiology meetings, the pharmacology emphasis was strong on balancing risks of stroke and bleeding in treating heart attacks and atrial fibrillation.

Meeting Highlights

In these two major cardiology meetings, the pharmacology emphasis was strong on balancing risks of stroke and bleeding in treating heart attacks and atrial fibrillation.

Book Review

In his exhaustively researched new book, Generic: The Unbranding of Modern Medicine, physician-historian Jeremy A. Greene, MD, PhD, explores the rise of generic drugs in the U.S. and our evolving understanding of “generic equivalence.”

P&T Snapshot
Respondents Weigh In on Adherence, Vision Screenings, Patient Support Programs, and E-Prescribing

A survey on the eye care market shows areas of agreement and a few sharp differences among ophthalmologists, optometrists, and managed care executives.

Departments

Medication Errors

Measuring mix-ups blamed for overdoses of insulin

Prescription: Washington

FDA draft guidance on 503B compounding widely faulted

FDA approvals, drug indications, and updates

Naltrexone/bupropion (Contrave) for weight management; pembrolizumab (Keytruda) for melanoma; dolutegravir/abacavir/lamivudine (Triumeq) for HIV-1; and immune globulin infusion 10% (human) with recombinant human hyaluronidase (Hyqvia) for primary immunodeficiency

Drug Forecast

Riociguat (Adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension